Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)." The 102-page submission marks a critical milestone in expanding the therapeutic reach of ACP-01. Plain-language summary:...
2025-10-09 9:03 AM EDT
Hemostemix's Insider Lead Order of $330,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subject to the following...
2025-10-07 10:05 AM EDT
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that it...
2025-09-23 12:22 PM EDT
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that Chief...
2025-09-17 7:52 AM EDT
Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina
Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that Croom Lawrence will...
2025-09-16 2:52 PM EDT
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces that it has...
2025-09-10 4:37 PM EDT
Hemostemix Announces Private Placement
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces a non brokered private...
2025-09-09 8:47 AM EDT
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
Calgary, Alberta--(Newsfile Corp. - September 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, announces the launch of a newly upgraded...
2025-09-09 6:13 AM EDT
Hemostemix's VesCell.Health Launched in Florida
Calgary, Alberta--(Newsfile Corp. - September 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, today announces it launched...
2025-09-04 9:47 AM EDT
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, celebrated the 17+ years of life gained...
2025-09-03 8:47 AM EDT
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
Calgary, Alberta--(Newsfile Corp. - August 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces it has organized patient financing for VesCell™...
2025-08-28 2:52 PM EDT
Hemostemix's Boots on the Ground in Florida
Calgary, Alberta--(Newsfile Corp. - August 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces the launch of its face-to-face sales program, with...
2025-08-26 9:12 AM EDT
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies...
2025-08-20 7:35 AM EDT
Hemostemix Announces Its AI Strategy
Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom Lawrence, Chief Commercialization Officer, Hemostemix, who completed...
2025-08-19 6:54 AM EDT
Hemostemix's Expands its Marketing Team Focused on Sales in Florida
Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat PAD & CLTI;...
2025-08-14 9:17 AM EDT
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it contracted Empire Market Ventures to provide an investor market awareness program. Empire Market Ventures (EMV) is a premier consulting firm and full-service advertising and investor awareness agency based in New York City. Specializing in strategic communications, digital media, and market intelligence, EMV delivers tailored solutions that enhance the visibility...
2025-08-12 10:01 AM EDT
Hemostemix Increases Previously Closed Private Placement to $3,000,000
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") wishes to provide an update regarding its previously closed non-brokered private placement (the "Offering"). The Company confirms that, following the receipt of additional subscriptions not included in the original Offering which closed on July 23, 2025, the size of the Offering has been increased from...
2025-07-31 5:53 PM EDT
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term performance of brain-computer interfaces (BCIs). Key Scientific Insights The...
2025-07-31 2:49 PM EDT
Hemostemix Closes $2,969,600 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 24, 2025) - Further to Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") June 26 and July 9th press releases, the Company is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of $2,969,600 from the sale of 29,696,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit. Each Unit was comprised of one common share...
2025-07-24 10:24 AM EDT
Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announced, further to its prior news...
2025-07-23 8:55 AM EDT